Eris Lifesciences Q2 FY27: revenue up 12.6% to Rs. 892 cr, PAT up 39.2%; gross margin levers from Zorvia out-licensing and Bhopal insulin shift
Q2 FY27 consolidated revenue up 12.6% to Rs. 892 cr, EBITDA up 7.3% to Rs. 309 cr, PAT up 39.2% to Rs. 187 cr.
By ScoutQuest · · 1 min read
- Q2 FY27 consolidated revenue
- Rs. 892 cr, up 12.6%
- Q2 FY27 EBITDA
- Rs. 309 cr, up 7.3% (34.7% margin, down from 36.4%)
- Q2 FY27 PAT
- Rs. 187 cr, up 39.2%
- Period
- Q2 & H1 FY27
- Positioning
- Eris describes itself as a chronic therapy focused domestic branded formulations franchise, 86% chronic and sub-chronic, with diabetes contributing 37.3% of its portfolio versus 9.5% for the market.
📈 Consolidated Q2 FY27 revenue was Rs. 892 cr, up 12.6%, with EBITDA of Rs. 309 cr (34.7% margin, down from 36.4%) and PAT of Rs. 187 cr, up 39.2%; adjusted PAT was Rs. 158 cr, up 17.5%. PAT was helped by a Rs. 65 cr positive tax impact from the NCLT merger order, offset partly by a ~36 cr receivables write-off.
🌍 The domestic branded business grew 14.1% to 809 cr in Q2; the company says growth ex-Zorvia was 16.5% and that all major therapies outgrew the market, with diabetes growth of 18.5% versus 16.1% for IPM.
🏭 Management states it expects ~100 bps gross margin gain from brands out-licensed to Zorvia and another ~100 bps from the commercialised Bhopal insulin facility, with a full manufacturing shift to Bhopal expected in the second half of next year.
📉 The company says the capex cycle is winding down by end of FY27 and that Eris Bionxt, Swiss and Levim investments should start returning from next year; ROCE was 19% YTD versus 16% in FY26 and net debt fell ~111 cr in H1. Swiss Parenterals revenue was flat with EBITDA margin down to 25.0% amid EU CAPA work.
Also from Eris Lifesciences
Eris Lifesciences posts Q2 FY27 earnings call recording held on October 26, 2026
26 Oct 2026
Board approves Q2/H1 FY2026 results; unmodified limited review; scheme of arrangement effective
26 Oct 2026
Eris Lifesciences schedules Q2 & H1 FY2027 earnings call for October 26, 2026 at 4:30 PM IST
19 Oct 2026
More numbers
- Consolidated revenue from operations, Q2 FY27Rs. 892 cr.
- Consolidated revenue growth, Q2 FY2712.6%
- Consolidated EBITDA, Q2 FY27Rs. 309 cr.
- Consolidated PAT, Q2 FY27Rs. 187 cr.
- PAT growth, Q2 FY2739.2%
- Adjusted PAT, Q2 FY27Rs. 158 cr.
- Consolidated revenue, H1 FY271,766 (Rs. Cr)
- DBF revenue, Q2 FY27809 (₹ Cr)
- DBF EBITDA margin, Q2 FY2735.7%
- DBF gross margin, Q2 FY2775.7%
- H1 capex, FY27Rs. 220 cr.
- ROCE, FY27 YTD19%
- Positive tax impact from NCLT merger orderRs. 65 cr
- Promoter shareholding, Sept 30, 202654.74%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.